Sangamo Therapeutics Stock Forecast for 2023 - 2025 - 2030
Updated on 05/03/2024
Sangamo Therapeutics Stock Forecast and Price Target
The average price target of $2.50 for Sangamo Therapeutics's stock set by distinguished analysts in recent weeks would represent a potential upside of approximately 380.77% from the last closing price in May, 2024 if reached by the end of the year. This potential increase is based on a high estimate of $8.00 and a low estimate of $1.00. If you want to invest in SGMO stock, you might also want to take a look at how its competitors are doing.
380.77% Upside
Sangamo Therapeutics Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, Sangamo Therapeutics's Price has grown, increasing from $0.00 to $0.00 – an increase of 100.00%. For next year, the 9 analysts predict Fair Value of $0.56, which would mean an increase of 100.00%. Over the next ten years, the pros' prediction is Fair Valueof $1.45, which would mean a ten-year growth forecast of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CRSP Stock Forecast | CRISPR Therapeutics | Outperform |
6
|
$55.07 | Buy/Sell | $86.67 | 58.89% |
| RGNX Stock Forecast | REGENXBIO | Outperform |
10
|
$16.64 | Buy/Sell | $34.70 | 137.38% |
| EDIT Stock Forecast | Editas Medicine | Outperform |
10
|
$5.62 | Buy/Sell | $14.87 | 166.90% |
| VYGR Stock Forecast | Voyager Therapeutics | Buy |
4
|
$8.53 | Buy/Sell | $13.67 | 111.02% |
| QURE Stock Forecast | uniQure N.V. | Outperform |
12
|
$4.68 | Buy/Sell | $27.83 | 353.85% |
Sangamo Therapeutics Revenue Forecast for 2023 - 2025 - 2030
In the last three years, Sangamo Therapeutics's Revenue has grown, increasing from $118.19M to $176.23M – an increase of 49.11%. According to 8 analysts, Sangamo Therapeutics's Revenue will fall by 75.87% in the next year, reaching $42.52M. Over the next thirteen years, the pros' prediction is Revenueof $644.29M, which would mean a thirteen-year growth forecast of 265.60%.
.jpg)
Sangamo Therapeutics EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, Sangamo Therapeutics's EBITDA has decreased from $-123.87M to $-87.43M – a 29.42% drop. For the next year, analysts are expecting EBITDA to reach $-101.55M – an increase of 16.15%. Over the next nine years, experts predict that EBITDA will grow by 103.00%.
Sangamo Therapeutics EBIT Forecast for 2023 - 2025 - 2030
Sangamo Therapeutics's EBIT has decreased by 20.89% In the last three years, from $-129.55M to $-102.49M. Next year, analysts are expecting EBIT to reach $-119.60M – an increase of 16.69%. According to professionals, by 2030, Sangamo Therapeutics's EBIT will have decreased by 391.82%, falling down to $299.09M.
Sangamo Therapeutics EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, Sangamo Therapeutics's EPS has grown, increasing from $-0.90 to $0.00 – an increase of 100.00%. For next year, the 9 analysts predict EPS of $-0.48, which would mean an increase of 100.00%. Over the next ten years, the pros' prediction is EPSof $1.19, which would mean a ten-year growth forecast of 100.00%.
.jpg)